Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

In this segment, the expert panel turns to the ophthalmologic perspective on ocular toxicities associated with antibody–drug conjugates (ADCs). The ophthalmologist outlines the most common eye-related adverse events—corneal epitheliopathy, dry eye disease, blurry vision, conjunctivitis, and occasional uveitis—emphasizing that most cases are mild and manageable with conservative measures such as lubricating drops. However, the panel stresses that more severe complications, including keratitis and persistent vision changes, may necessitate treatment delays or dose adjustments, highlighting the need for coordinated care between oncology and ophthalmology. The discussion focuses on red-flag symptoms that should prompt urgent referral: significant or persistent vision changes affecting daily activities, marked light sensitivity suggestive of intraocular inflammation, and symptoms that do not improve with initial supportive care. The faculty underscore that early ophthalmologic evaluation can prevent progression, support timely therapeutic decisions, and facilitate safer continuation of ADC therapy, reinforcing the importance of collaborative management in this emerging area.